The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial.
Hagen SchwenzerErica De ZanMustafa ElshaniRuud van StiphoutMary KudsyJosephine MorrisValentina FerrariIn Hwa UmJames ChettleFarasat KazmiLeticia CampoAlistair EastonSebastian NijmanMichaela SerpiStefan N SymeonidesRuth PlummerDavid J HarrisonGareth BondSarah P BlagdenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Our study provides proof that NUC-7738 overcomes cellular resistance mechanisms and supports its further clinical evaluation as a novel cancer treatment within the growing pantheon of anticancer ProTides.